Drugs / MBL-HCV1
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00952263 | Jul → Dec 2009 | — | MassBiologics | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01532908 | Nov 2012 → Aug 2015 | chronic hepatitis C virus infection | MassBiologics | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT01121185 | Jun 2010 → Jun 2011 | hepatitis C virus infection | MassBiologics | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MBL-HCV1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00952263 ↗ |
| Modality | Monoclonal antibody | “human monoclonal antibody MBL-HCV1” NCT00952263 ↗ |
| Route | Other | “Single infusion of MBL-HCV1 at escalating doses” NCT00952263 ↗ |